This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (199)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Hypertension  • Review  • Prognosis/ Outcomes  • Alert me on articles by topic

A Network Meta-analysis

Bruce M. Psaty, MD, PhD; Thomas Lumley, PhD; Curt D. Furberg, MD, PhD; Gina Schellenbaum; Marco Pahor, MD; Michael H. Alderman, MD; Noel S. Weiss, MD, DrPH

JAMA. 2003;289:2534-2544.

Context  Establishing relative benefit or harm from specific antihypertensive agents is limited by the complex array of studies that compare treatments. Network meta-analysis combines direct and indirect evidence to better define risk or benefit.

Objective  To summarize the available clinical trial evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major cardiovascular disease end points and all-cause mortality.

Data Sources and Study Selection  We used previous meta-analyses, MEDLINE searches, and journal reviews from January 1995 through December 2002. We identified long-term randomized controlled trials that assessed major cardiovascular disease end points as an outcome. Eligible studies included both those with placebo-treated or untreated controls and those with actively treated controls.

Data Extraction  Network meta-analysis was used to combine direct within-trial between-drug comparisons with indirect evidence from the other trials. The indirect comparisons, which preserve the within-trial randomized findings, were constructed from trials that had one treatment in common.

Data Synthesis  Data were combined from 42 clinical trials that included 192 478 patients randomized to 7 major treatment strategies, including placebo. For all outcomes, low-dose diuretics were superior to placebo: coronary heart disease (CHD; RR, 0.79; 95% confidence interval [CI], 0.69-0.92); congestive heart failure (CHF; RR, 0.51; 95% CI, 0.42-0.62); stroke (RR, 0.71; 0.63-0.81); cardiovascular disease events (RR, 0.76; 95% CI, 0.69-0.83); cardiovascular disease mortality (RR, 0.81; 95% CI, 0.73-0.92); and total mortality (RR, 0.90; 95% CI, 0.84-0.96). None of the first-line treatment strategies–-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), -blockers, and angiotensin receptor blockers–was significantly better than low-dose diuretics for any outcome. Compared with CCBs, low-dose diuretics were associated with reduced risks of cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00) and CHF (RR, 0.74; 95% CI, 0.67-0.81). Compared with ACE inhibitors, low-dose diuretics were associated with reduced risks of CHF (RR, 0.88; 95% CI, 0.80-0.96), cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00), and stroke (RR, 0.86; 0.77-0.97). Compared with -blockers, low-dose diuretics were associated with a reduced risk of cardiovascular disease events (RR, 0.89; 95% CI, 0.80-0.98). Compared with -blockers, low-dose diuretics were associated with reduced risks of CHF (RR, 0.51; 95% CI, 0.43-0.60) and cardiovascular disease events (RR, 0.84; 95% CI, 0.75-0.93). Blood pressure changes were similar between comparison treatments.

Conclusions  Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality. Clinical practice and treatment guidelines should reflect this evidence, and future trials should use low-dose diuretics as the standard for clinically useful comparisons.

Author Affiliations: Departments of Medicine (Dr Psaty), Epidemiology (Drs Psaty and Weiss and Ms Schellenbaum), Health Services (Drs Psaty), and Biostatistics (Dr Lumley), Cardiovascular Health Research Unit, University of Washington, Seattle; Departments of Public Health Sciences (Dr Furberg) and Medicine (Dr Pahor), Wake Forest University Health Sciences, Winston-Salem, NC; and Department of Epidemiology and Social Medicine (Dr Alderman), Albert Einstein College of Medicine, Bronx, NY.

RELATED LETTERS

The JNC 7 Hypertension Guidelines
Hean Teik Ong
JAMA. 2003;290(10):1312.
EXTRACT | FULL TEXT  

Meta-analysis of Health Outcomes of Chlorthalidone-Based vs Nonchlorthalidone-Based Low-Dose Diuretic Therapies
Bruce M. Psaty, Thomas Lumley, and Curt D. Furberg
JAMA. 2004;292(1):43-44.
EXTRACT | FULL TEXT  

RELATED ARTICLES

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
Aram V. Chobanian, George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo, Jr, Daniel W. Jones, Barry J. Materson, Suzanne Oparil, Jackson T. Wright, Jr, and Edward J. Roccella
JAMA. 2003;289(19):2560-2571.
ABSTRACT | FULL TEXT  

JNC 7—It's More Than High Blood Pressure
Thomas E. Kottke, Robert J. Stroebel, and Rebecca S. Hoffman
JAMA. 2003;289(19):2573-2575.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
Stettler et al.
BMJ 2008;337:a1331-a1331.
ABSTRACT | FULL TEXT  

Graphical exploration of network meta-analysis data: the use of multidimensional scaling
Chung and Lumley
Clin Trials 2008;5:301-307.
ABSTRACT  

Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute
Carter et al.
Hypertension 2008;52:30-36.
FULL TEXT  

Evaluation of networks of randomized trials
Salanti et al.
Stat Methods Med Res 2008;17:279-301.
ABSTRACT  

Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension
Cutler and Davis
Circulation 2008;117:2691-2705.
FULL TEXT  

Absolute Cardiovascular Disease Risk and Shared Decision Making in Primary Care: A Randomized Controlled Trial
Krones et al.
Ann Fam Med 2008;6:218-227.
ABSTRACT | FULL TEXT  

Network meta-analysis of antiplatelet treatments for secondary stroke prevention
Baumgartner
Eur Heart J 2008;29:1082-1083.
FULL TEXT  

Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke
Thijs et al.
Eur Heart J 2008;29:1086-1092.
ABSTRACT | FULL TEXT  

Exploring the Geometry of Treatment Networks
Salanti et al.
ANN INTERN MED 2008;148:544-553.
ABSTRACT | FULL TEXT  

Predicting Stroke Risk in Hypertensive Patients With Coronary Artery Disease: A Report From the INVEST
Coca et al.
Stroke 2008;39:343-348.
ABSTRACT | FULL TEXT  

Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker
Prisant
J Clin Pharmacol 2008;48:225-239.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients
Okin et al.
ANN INTERN MED 2007;147:311-319.
ABSTRACT | FULL TEXT  

Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review
Park and Taylor
Ann Fam Med 2007;5:444-452.
ABSTRACT | FULL TEXT  

Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence
Bangalore et al.
J Am Coll Cardiol 2007;50:563-572.
ABSTRACT | FULL TEXT  

Predictive Utility of Pulse Pressure and Other Blood Pressure Measures for Cardiovascular Outcomes
Mosley et al.
Hypertension 2007;49:1256-1264.
ABSTRACT | FULL TEXT  

First-Line Therapy for Hypertension
Eledrisi
ANN INTERN MED 2007;146:615-615.
FULL TEXT  

Do {beta}-blockers have a role in treating hypertension?: YES
Khan and McAlister
cfp 2007;53:614-617.
FULL TEXT  

Les betabloquants ont-ils un role dans le traitement de l'hypertension?: OUI
Khan and McAlister
cfp 2007;53:618-621.
FULL TEXT  

Blood Pressure in Heart Failure: A Love-Hate Relationship
Pfeffer
J Am Coll Cardiol 2007;49:40-42.
FULL TEXT  

Screening Children to Identify Families at Increased Risk for Cardiovascular Disease
Reis et al.
Pediatrics 2006;118:e1789-e1797.
ABSTRACT | FULL TEXT  

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments.
Kyrgiou et al.
JNCI J Natl Cancer Inst 2006;98:1655-1663.
ABSTRACT | FULL TEXT  

Heart Failure, Dementia, and Diuretics: Is Uric Acid Involved?--Reply
Qiu et al.
Arch Intern Med 2006;166:2287-2287.
FULL TEXT  

Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004
Ma et al.
Hypertension 2006;48:846-852.
ABSTRACT | FULL TEXT  

Abstract 2752: Prevention of Stroke by Antihypertensive Drugs: An Updated Network Meta-analysis
Elliott and Meyer
Circulation 2006;114:II_575-II_575.
 

Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies.
Gemmell et al.
Qual Saf Health Care 2006;15:339-343.
ABSTRACT | FULL TEXT  

Clinical Trials in Hypertension--Reply
Psaty et al.
JAMA 2006;296:1464-1465.
FULL TEXT  

Gout, not induced by diuretics? A case-control study from primary care
Janssens et al.
Ann Rheum Dis 2006;65:1080-1083.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Knight and Fihn
ANN INTERN MED 2006;145:52-61.
FULL TEXT  

Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care?
Sawicki and McGauran
Hypertension 2006;48:1-7.
FULL TEXT  

Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
Cooper et al.
Arch Intern Med 2006;166:1269-1275.
ABSTRACT | FULL TEXT  

Re-examining the efficacy of {beta}-blockers for the treatment of hypertension: a meta-analysis
Khan and McAlister
CMAJ 2006;174:1737-1742.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Treatment of Hypertension.
Zillich and Haines
Am J Health Syst Pharm 2006;63:1074-1080.
FULL TEXT  

Recent Trials in Hypertension: Compelling Science or Commercial Speech?
Psaty et al.
JAMA 2006;295:1704-1706.
FULL TEXT  

Diuretic usage in heart failure: a continuing conundrum in 2005
Jolobe
Eur Heart J 2006;27:886-887.
FULL TEXT  

Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs?
Blankfield
J Am Board Fam Med 2006;19:178-182.
ABSTRACT | FULL TEXT  

Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure
Ernst et al.
Hypertension 2006;47:352-358.
ABSTRACT | FULL TEXT  

Statin and beta-blocker therapy and the initial presentation of coronary heart disease.
Go et al.
ANN INTERN MED 2006;144:229-238.
ABSTRACT | FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Simultaneous comparison of multiple treatments: combining direct and indirect evidence
Caldwell et al.
BMJ 2005;331:897-900.
FULL TEXT  

Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
Khan et al.
CMAJ 2005;173:865-867.
FULL TEXT  

Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients
Hemmelgarn et al.
CMAJ 2005;173:593-595.
FULL TEXT  

Epidemiology of Uncontrolled Hypertension in the United States
Wang and Vasan
Circulation 2005;112:1651-1662.
FULL TEXT  

Diuretics for Hypertension
Krakoff
Circulation 2005;112:e127-e129.
FULL TEXT  

Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis
McManus et al.
BMJ 2005;331:493.
ABSTRACT | FULL TEXT  

Persistence with Treatment in Newly Treated Middle-Aged Patients with Essential Hypertension
Perreault et al.
The Annals of Pharmacotherapy 2005;39:1401-1408.
ABSTRACT | FULL TEXT  

Hypertension in Adults Across the Age Spectrum: Current Outcomes and Control in the Community
Lloyd-Jones et al.
JAMA 2005;294:466-472.
ABSTRACT | FULL TEXT  

Challenges in Systematic Reviews That Evaluate Drug Efficacy or Effectiveness
Santaguida et al.
ANN INTERN MED 2005;142:1066-1072.
ABSTRACT | FULL TEXT  

Diuretic based therapy reduced CV mortality in older patients with isolated systolic hypertension and diabetes
Alkhenizan
Evid. Based Med. 2005;10:75-75.
FULL TEXT  

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
Wright et al.
JAMA 2005;293:1595-1608.
ABSTRACT | FULL TEXT  

Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes
Blankfield
J Am Board Fam Med 2005;18:113-124.
ABSTRACT | FULL TEXT  

Novel Approach to Examining First Cardiovascular Events After Hypertension Onset
Lloyd-Jones et al.
Hypertension 2005;45:39-45.
ABSTRACT | FULL TEXT  

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study
Kizer et al.
Hypertension 2005;45:46-52.
ABSTRACT | FULL TEXT  

Translating Research into Practice: Are Physicians Following Evidence-Based Guidelines in the Treatment of Hypertension?
Holmes et al.
Med Care Res Rev 2004;61:453-473.
ABSTRACT  

Management of Hypertension in the Very Elderly Patient
Elliott
Hypertension 2004;44:800-804.
ABSTRACT | FULL TEXT  

Arterial Pressure Lowering Effect of Chronic Atenolol Therapy in Hypertension and Vasoconstrictor Sympathetic Drive
Burns et al.
Hypertension 2004;44:454-458.
ABSTRACT | FULL TEXT  

Outcomes for thiazides are similar
BMJ 2004;329:.
FULL TEXT  

Predictors of Heart Failure Among Women With Coronary Disease
Bibbins-Domingo et al.
Circulation 2004;110:1424-1430.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Kroenke and Logio
ANN INTERN MED 2004;141:213-220.
FULL TEXT  

Meta-analysis of Health Outcomes of Chlorthalidone-Based vs Nonchlorthalidone-Based Low-Dose Diuretic Therapies
Psaty et al.
JAMA 2004;292:43-44.
FULL TEXT  

ALLHAT: Setting the Record Straight
Davis et al.
ANN INTERN MED 2004;141:39-46.
ABSTRACT | FULL TEXT  

Chronic Management of Blood Pressure After Stroke
Pedelty and Gorelick
Hypertension 2004;44:1-5.
FULL TEXT  

Hypertensive Therapy: Part II
Franco et al.
Circulation 2004;109:3081-3088.
FULL TEXT  

A putative placebo comparison of the SCOPE and LIFE trials
Meredith et al.
Journal of Renin-Angiotensin-Aldosterone System 2004;5:59-63.
ABSTRACT  

Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?
Fischer and Avorn
JAMA 2004;291:1850-1856.
ABSTRACT | FULL TEXT  

Review: low dose diuretics are the best first line antihypertensive treatment
Davidson
Evid. Based Med. 2004;9:12-12.
FULL TEXT  

The Return on INVEST
Alderman
JAMA 2003;290:2859-2861.
FULL TEXT  

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT | FULL TEXT  

Starting Earlier to Prevent Heart Disease
McGill and McMahan
JAMA 2003;290:2320-2322.
FULL TEXT  

OTHER ARTICLES NOTED (25 Apr 2003 to 18 Jul 2003)
Evid. Based Nurs. 2003;6:e1-12.
FULL TEXT  

The JNC 7 Hypertension Guidelines
Ong
JAMA 2003;290:1312-1312.
FULL TEXT  

Diuretics should be first line treatment for hypertension
BMJ 2003;327:0-0.
FULL TEXT  

Guiding Lights for Antihypertensive Treatment in Patients with Nondiabetic Chronic Renal Disease: Proteinuria and Blood Pressure Levels?
Mulrow and Townsend
ANN INTERN MED 2003;139:296-298.
FULL TEXT  

New Hypertension Guidelines: JNC 7
JWatch Gastroenterology 2003;2003:9-9.
FULL TEXT  

Guidelines: Hypertension Prevention and Management -- JNC 7
Journal Watch Cardiology 2003;2003:1-1.
FULL TEXT  

New Hypertension Guidelines: JNC 7
JWatch General 2003;2003:1-1.
FULL TEXT